Completed
A Phase I Dose Escalation Study of CGM097 in Adult Patients With Selected Advanced Solid Tumors
NCT01760525
- Conditions
- Solid Tumor With p53 Wild Type Status
- Locations
-
- Dana Farber Cancer Institute SC (2) Boston, Massachusetts, United States
- Novartis Investigative Site Lyon, France
- Novartis Investigative Site Essen, Germany
- Novartis Investigative Site Singapore